Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC)

被引：0
作者：
Gainor, J. F. [1 ]
Curigliano, G. [2 ]
Kim, D. -W. [3 ]
Lee, D. H. [4 ]
Besse, B. [5 ]
Baik, C. S. [6 ]
Doebele, R. C. [7 ]
Cassier, P. [8 ]
Lopes, G. [9 ]
Tan, D. S. -W. [10 ]
Garralda, E. [11 ]
Paz-Ares, L. [12 ]
Cho, B. C. [13 ]
Gadgeel, S. M. [14 ]
Thomas, M. [15 ]
Liu, S. V. [16 ]
Clifford, C. [17 ]
Zhang, H. [17 ]
Turner, C. D. [17 ]
Subbiah, V. [18 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[3] Seoul Natl Univ Hosp, Seoul, South Korea
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Gustave Roussy Univ Paris Sud, Villejuif, France
[6] Univ Washington, Sch Med, Main Hosp Seattle, Seattle, WA 98195 USA
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
[8] Ctr Leon Berard, Lyon, France
[9] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[10] Natl Canc Ctr Singapore, Singapore, Singapore
[11] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[12] Hosp Univ 12 Octubre, Madrid, Spain
[13] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[14] Henry Ford Canc Inst, Detroit, MI USA
[15] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[16] Georgetown Univ, Washington, DC USA
[17] Blueprint Med Corp, Cambridge, MA USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO01.38
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [31] AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC
    Besse, B.
    Felip, E.
    Kim, E. S.
    Clifford, C.
    Louie-Gao, M.
    Yagui-Beltran, A.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S684 - S684
  • [32] Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study (vol 22, pg 959, 2021)
    Gainor, Justin F.
    Curigliano, Giuseppe
    Kim, Dong-Wan
    Lee, Dae Ho
    Besse, Benjamin
    Baik, Christina S.
    Doebele, Robert C.
    Cassier, Philippe A.
    Lopes, Gilberto
    Tan, Daniel S. W.
    Garralda, Elena
    Paz-Ares, Luis G.
    Cho, Byoung Chul
    Gadgeel, Shirish M.
    Thomas, Michael
    Liu, Stephen V.
    Taylor, Matthew H.
    Mansfield, Aaron S.
    Zhu, Viola W.
    Clifford, Corinne
    Zhang, Hui
    Palmer, Michael
    Green, Jennifer
    Turner, Christopher D.
    Subbiah, Vivek
    LANCET ONCOLOGY, 2021, 22 (08) : E347 - E347
  • [33] Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
    Subbiah, Vivek
    Hu, Mimi, I
    Wirth, Lori J.
    Schuler, Martin
    Mansfield, Aaron S.
    Curigliano, Giuseppe
    Brose, Marcia S.
    Zhu, Viola W.
    Leboulleux, Sophie
    Bowles, Daniel W.
    Baik, Christina S.
    Adkins, Douglas
    Keam, Bhumsuk
    Matos, Ignacio
    Garralda, Elena
    Gainor, Justin F.
    Lopes, Gilberto
    Lin, Chia-Chi
    Godbert, Yann
    Sarker, Debashis
    Miller, Stephen G.
    Clifford, Corinne
    Zhang, Hui
    Turner, Christopher D.
    Taylor, Matthew H.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (08) : 491 - 501
  • [34] Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy
    Zhou, Q.
    Wu, Y.
    Chang, J.
    Fan, Y.
    Zhao, J.
    Wu, G.
    Sun, Y.
    Wang, X.
    Nian, W.
    Wang, K.
    Zheng, X.
    Qu, L.
    Yao, S.
    Liu, K.
    Li, P.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S100 - S100
  • [35] Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
    Johnson, DH
    Paul, DM
    Hande, KR
    Shyr, Y
    Blanke, C
    Murphy, B
    Lewis, M
    DeVore, RF
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2054 - 2060
  • [36] Selpercatinib (LOXO-292) in patients with RET-fusion plus non-small-cell lung cancer
    Goto, K.
    Oxnard, G.
    Tan, D. S. -W.
    Loong, H. H. F.
    Bauer, T.
    Gainor, J.
    McCoach, C.
    Gautschi, O.
    Besse, B.
    Cho, B. C.
    Peled, N.
    Weiss, J.
    Kim, Y. J.
    Ohe, Y.
    Horiike, A.
    Park, K.
    Huang, X.
    Olek, E.
    Subbiah, V.
    Drilon, A.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 7S
  • [37] Selpercatinib (LOXO-292) in patients with RET-fusion plus Non-Small-Cell Lung Cancer
    Gautschi, O.
    Goto, K.
    Oxnard, G.
    Tan, D. S. -W.
    Loong, H. H. F.
    Bauer, T.
    Gainor, J.
    McCoach, C.
    Besse, B.
    Cho, B. C.
    Peled, N.
    Weiss, J.
    Kim, Y. J.
    Ohe, Y.
    Horiike, A.
    Park, K.
    Huang, X.
    Olek, E.
    Subbiah, V.
    Drilon, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 149 - 150
  • [38] Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Rubinsak, J. R.
    Spigel, D. R.
    Hainsworth, J. D.
    Webb, C.
    Inhorn, R. C.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E. R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Brachytherapy plus chemotherapy in advanced non small cell lung cancer (NSCLC) phase II trial
    Grigorescu, A
    Bacinschi, X
    Radoi, S
    Ciocaltei, V
    LUNG CANCER, 2005, 49 : S380 - S380
  • [40] Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Al Khayat, Mohamed N. M. T.
    Armstrong, Nigel
    Howick, Jeremy
    O'Meara, Susan
    Posadzki, Pawel
    Ryder, Steve
    Ahmadu, Charlotte
    Konings, Stefan R. A.
    Postma, Maarten J.
    Duffy, Steven
    Wolff, Robert F.
    van Asselt, Antoinette D. I.
    PHARMACOECONOMICS, 2023, 41 (04) : 353 - 361
12345